More progress, more hope
Dear Friends and Partners,

Like compounding interest, the accumulated impact of our work together over the past 12 years has made possible more progress on more fronts this year than ever before. And, with that progress, more reasons to be hopeful about the future.

In the pages that follow, you’ll see how the pipeline of new treatment options for chordoma continues to grow, from the launch of two new CF-supported clinical trials in 2018 to investments in basic and translational research that are feeding new treatment ideas into that pipeline. You’ll read about our first major foray into new drug discovery, and how our research partners are applying innovative and truly remarkable technologies to develop drugs against brachyury—the Achilles’ heel of chordoma. And, you’ll learn about valuable new resources we rolled out to help make the journey with chordoma feel less lonely and less bewildering.

But, most importantly, this report is a tribute to you—the volunteers, donors, partners, and advisors who make our work possible and propel our mission forward. Thank you for being a part of this movement. Thank you for helping to set the bar for catalyzing progress against a rare cancer. And thank you for giving all of us affected by chordoma reasons to hope. Because of you, I know chordoma is a solvable problem, and I look forward to continuing to work with you to solve it. Onward!

Josh Sommer
Co-Founder and Executive Director
13-Year Survivor

Table of contents

2 Research
12 Patient Services
16 Uncommon Awards
18 Thank you to our supporters
24 Financials
25 Looking ahead
26 Our team

Josh Sommer
Co-Founder and Executive Director
13-Year Survivor

Improving the lives of those affected by chordoma.

Leading the search for a cure.
Most notably, as described in the following pages, we focused on driving progress in four key areas:

1. **Bringing research advances to pediatric chordoma**
2. **Jumpstarting brachyury drug discovery**
3. **Expanding the pipeline of chordoma clinical trials**
4. **Expanding the chordoma research network**

Read on to learn more »
Jumpstarting brachyury drug discovery

The most important insight about chordoma that research has revealed to date is that it has an Achilles’ heel: a protein called brachyury. Not only is brachyury the defining feature of chordoma, but chordoma cells cannot survive without it. With no known function in normal cells, targeting brachyury represents the greatest opportunity to defeat chordoma without harming the patient.

It also turns out that brachyury plays a role in metastasis in a number of other cancers such as breast, lung, colon, and prostate, so therapies against brachyury could have an impact far beyond chordoma. The challenge, however, is that brachyury belongs to a class of proteins called transcription factors, which have historically been considered “undruggable” because they lack the types of nooks, crannies, and crevices to which most drugs bind. Fortunately, several emerging technologies have the potential to overcome this barrier.

In the first year, the goal of these projects is to discover chemical compounds that bind to the brachyury protein — a critical first step in developing drugs that can inhibit or degrade brachyury.

The Foundation’s active role in bringing together research groups with complementary capabilities will probably shorten the time to achieve our goals by at least 50%.

Opher Gileadi, PhD
University of Oxford

Craig Crews, PhD (Yale University)
Identifying brachyury binders through computational modeling, and attempting to eliminate brachyury by harnessing the innate cellular system for destroying faulty proteins, a process called targeted protein degradation.

Daniel Nomura, PhD (University of California, Berkeley)
Employing novel chemistry techniques to discover molecules that bind strongly and irreversibly to the brachyury protein, providing a foothold for constructing compounds that either directly inhibit brachyury’s function or trigger its degradation. This work is part of a broader project funded by The Mark Foundation for Cancer Research to target “undruggable” proteins implicated in cancer.

Opher Gileadi, PhD (Oxford University)
David Drewry, PhD (University of North Carolina, Chapel Hill)
Charles Lin, PhD (Baylor College of Medicine)
Developing a high-resolution map of the physical structure of the brachyury protein and constructing drugs based on identifying small chemical structures (“chemical fragments”) that interface with subtle features in the protein.

In partnership with The Mark Foundation for Cancer Research, we awarded pilot grants to support three projects applying cutting-edge technologies to brachyury drug discovery.
Expanding the clinical trials pipeline

Two CF-supported clinical trials opened in 2018, bringing the total number of open trials in our pipeline to five — halfway to our goal of ten by 2020.

The first trial is testing the effectiveness of the FDA-approved targeted therapy afatinib, which blocks a protein called EGFR that plays an important role in driving chordoma. The second is evaluating the effectiveness of an experimental cancer vaccine called BN-Brachyury, which is designed to harness the immune system to attack cells in which brachyury is produced.

Looking for a clinical trial that may be right for you?
Our Clinical Trials Catalogue lists all chordoma-specific trials as well as all other trials deemed relevant to chordoma patients by our Medical Advisory Board (MAB). It currently includes information on 17 trials worldwide.
chordoma.org/clinical-trials

<table>
<thead>
<tr>
<th>Planning</th>
<th>Active</th>
<th>Results available</th>
</tr>
</thead>
</table>
| GI-6301 with radiation
Brachyury vaccine | | |
| Nivolumab with radiation
PD-1 inhibitor | | |
| Afatinib
EGFR inhibitor | | |
| Palbociclib
CDK4/6 inhibitor | | |
| BN-brachyury vaccine
with radiation | | |
| Oncolytic
tumor bacteria | | |
| Autologous tumor
vaccine | | |
| EGFR
antibody | | |

The challenges of doing research in rare cancers often deter companies from investing in developing drugs for these patient populations, despite the significant unmet need. But the Chordoma Foundation has made it feasible for companies like ours to pursue drug development for this rare tumor type. Working with the Foundation was critical to enabling us to open and quickly enroll patients into the BN-brachyury vaccine trial.”

Chris Heery, MD
Chief Medical Officer,
Bavarian Nordic
Expanding the chordoma research network

After more than a decade of cultivating interest in chordoma and attracting researchers into the field, today, we are grateful to be working with a network of more than 350 research collaborators and 12 pharmaceutical and biotech companies. And, as the bleeding edge of chordoma research continues to expand into new areas, we are working proactively to recruit the most talented scientists in those areas to turn their attention to chordoma.

Expanding chordoma research in Canada

Through a joint grants program with the Canadian Cancer Society, we awarded two $150,000 grants in 2018 to outstanding physician scientists whose work is breaking new ground in understanding chordoma biology and identifying new treatment approaches.

- **Dr. Stephen Yip, MD, PhD (BC Cancer Agency)** is working to identify epigenetic drugs that can make chordoma more susceptible to immune attack and thus make immunotherapies more effective.

- **Dr. Gelareh Zadeh, MD, PhD (University of Toronto)** is undertaking the largest study to-date to characterize epigenetic alterations in chordoma and identify new epigenetic targets.

Currently funded researchers

- Cameron Brennan, MD, PhD - Memorial Sloan Kettering Cancer Center
- Craig Crewe, PhD* - Yale University
- David Drewry, PhD* - University of North Carolina
- Adrienne Flanagan MD, PhD - University College London
- Hans Gelderblom, MD, PhD - Leiden University Medical Center
- Opher Gileadi, PhD* - Oxford University
- Michael Kelley, MD - Duke University
- Michael Lim, MD - Johns Hopkins
- Charles Lin, PhD* - Baylor College of Medicine
- Dan Nomura, PhD** - UC Berkeley
- Slim Sassi, PhD - Massachusetts General Hospital
- Stuart Schreiber, PhD - Broad Institute of Harvard and MIT
- Yoshiya (Josh) Yamada, MD - Memorial Sloan Kettering Cancer Center
- Stephen Yip, MD, PhD** - BC Cancer Agency
- Gelareh Zadeh, MD, PhD** - University of Toronto

*2018 Grantees
+ Funded through partner organization
Uniting the global chordoma community

In March, a record number of participants joined us in Boston for the sixth International Chordoma Research Workshop (ICRW) and International Chordoma Community Conference (ICCC).

Together, these two conferences serve as the principal gathering points for the worldwide chordoma research and patient communities, providing a unique opportunity to forge relationships and share the latest research and treatment advances. Hosted back to back, they also serve as an important bridge between the researchers working to find better treatments and the individuals who stand to benefit from their work.

140 doctors and scientists

100 patients and caregivers

10 countries

70 institutions
Patient Services

This year, a record number of patients and families turned to the Foundation for information, guidance, and support through their journey with chordoma. To better meet their needs, we developed a host of new educational resources and launched a new, private online community called Chordoma Connections to facilitate more peer-to-peer knowledge sharing and support among patients and caregivers.

Aaron’s story

Aaron McMahon, a sports-loving teen from County Cork, Ireland, was diagnosed with a skull base chordoma in March of 2017 at just 16 years old.

After undergoing surgery in Ireland and radiation in Germany, Aaron and his family were optimistic chordoma would be behind them. So, when, just a few months later, his tumor started growing again, they were devastated. Aaron’s doctors told the family there was nothing more they could do.

But at 16 years old, with his whole life ahead of him, Aaron and his parents refused to give up hope. Instead, they made contact with our Patient Navigators who helped the family understand their treatment options, connect with fellow patients, and meet Dr. Paul Gardner, a neurosurgeon and chordoma expert at the University of Pittsburgh Medical Center (UPMC).

After learning that he was, in fact, a candidate for surgery, Aaron and his family were elated. They felt as if he had been granted a second chance. Aaron’s whole community rallied behind him, launching an all-out fundraising campaign to get him the care he needed. Through fundraisers, personal donations, and even a music video, they raised over €100,000 within a matter of months to send Aaron to Pittsburgh.

In June of 2018, Aaron underwent surgery at UPMC to remove the tumor that his local doctors told him was inoperable. Amazingly, they were able to remove the entire tumor, and Aaron made it through surgery with flying colors. Following surgery, Aaron’s diagnosis was revised to chondrosarcoma, a tumor for which chordoma is often misdiagnosed. Thanks to the help he received, Aaron is now back in Ireland preparing to start college and looking forward to a bright future.

Expert Recommendations for the Treatment of Recurrent Chordoma

Our newest educational booklet helps patients and caregivers facing a recurrence learn about and act upon evidence-based treatment guidelines developed by top chordoma experts.

chordoma.org/educational-materials

560+
Patient Navigation cases served

6,300+
views of our Doctor Directory

200K
views of “Living with chordoma” section of our website

ABOVE
Aaron McMahon with
Dr. Paul Gardner at the
University of Pittsburgh Medical Center; Article about Aaron and his family in the Irish Examiner
I am so proud of the Foundation’s work to build this community and so grateful for the opportunity to serve as a moderator. Though it may seem like that role is about helping others, I have found that it is helping me, too. After losing my husband to chordoma, it has been a privilege to share connections with others who have experienced some of the same things I have, and help each other move forward together.”

Kris Stahl
Chordoma Foundation Peer Guide and co-moderator of Chordoma Connections

Since launching in January, more than 650 patients and caregivers worldwide have joined the conversation in Chordoma Connections, the Foundation’s private online community. They come from many different backgrounds, countries, and cultures, but they all share one thing in common — the experience of having had their lives forever changed by chordoma.

Chordoma Connections offers a space where individuals affected by chordoma can turn to ask questions, share experiences, and get support from others who understand and have walked their same path. From insights on pain management, systemic therapy, side effects of treatment, or how to cope with survivorship, it’s all there.

community.chordoma.org

650+ members
36 states in the U.S.
50 countries
300+ discussion threads
8 private groups
Uncommon Awards

Uncommon Action
Chris Jones
For his consistent teaching, guidance, and support of fellow patients and caregivers as a Peer Guide, a moderator of the Chordoma Survivors group on Facebook, and Chair of our Community Advisory Board.

“While my daughter’s disease ultimately ran its course, it didn’t need to – or at least not so soon – had it been properly diagnosed initially. I remain committed to the Chordoma Foundation and to helping them improve the lives of people impacted by chordoma, and provide patients and families with support in navigating this challenging journey.”

Uncommon Champion
Steven Mandel
For his extraordinary fundraising efforts through #TeamChordoma, which have raised nearly $300,000 for the Foundation since 2014.

“Five years ago, when we started our half marathon fundraiser, it was just me and four friends. Today, we have more than 60 runners on #TeamChordoma. This event has become a staple at the Foundation, and I hope it serves as a grassroots model for many others in the community to kick-start their own #TeamChordoma fundraiser.”

Uncommon Champions
Team Fat Boys
Slim Sisters
For raising more than $300,000 in honor of one of their own — chordoma survivor Todd Balf — to support cutting edge chordoma research in the lab of Cigall Kadoch at Dana-Farber Cancer Institute.

“Although I joked that having chordoma was proof of what I’d always maintained — that I was one in a million — the recovery was harder than I could have ever imagined. In addition to my family, one of the things that most motivated me in my recovery was to try to get back on the bicycle and ride again. Being on the bike, surrounded by the whole team, felt like the best normal ever. To have that kind of support was incredible, and something I’ll never forget.”
— Todd Balf, chordoma survivor

Uncommon Collaboration
Ulm and Heidelberg Chordoma Research Teams
For working together to make great strides in chordoma research, including the discovery of a new therapeutic target, and, most recently, launching a clinical trial for chordoma patients.

“I am truly amazed by the collaborative spirit that the Foundation fosters in this field. Our team in Heidelberg is happy to be a part of it, and we look forward to continuing to make progress with our friends and colleagues at Ulm University.”
— Stefan Fröhling, Heidelberg University Chordoma Research Team

Uncommon Insight
Opher Gileadi, Oxford University
For solving the crystal structure of brachyury, a vital step both toward understanding how brachyury drives chordoma and developing new therapies that target brachyury.

“Normally, this type of discovery would take months to reach publication, and then maybe years to be exploited. But with the help of the Foundation, we immediately formed a network of collaborating experts in chemistry, cell biology, crystallography, and disease biology, and we’re already moving forward to discover inhibitors of brachyury.”

Uncommon Perseverance
Joel Beckman
For his extraordinary contributions to the Foundation as a leader on the Board of Directors, Chair of the Development Committee, mentor and guide to fellow patients, successful fundraiser, and transformational donor.

“Chordoma has been a major battle for me and I’m incredibly happy to be here nine years after being diagnosed, during which time I have seen both of my sons married and my two grandchildren born. The Chordoma Foundation is saving lives and improving the lives of so many individuals confronting the disease. I’m truly amazed when I look at the progress the Foundation has helped to achieve in such a short time. And I’m so proud that I’m able to play a role in such an extraordinary organization.”

Our Uncommon Awards recognize members of our community who exemplify the qualities necessary for success in the fight against chordoma.
Thank you for your support

We are filled with gratitude for all you have done for chordoma patients and families over the past year. You gave your time, your money and your heart to this uncommon community, creating a great and lasting impact.

$2.5M contributed

2018 Online Fundraising Champions

- Gail Baker  Since 2018
- Daniele Bananto  Since 2018
- Matt Berger  Since 2018
- Sharon Berlan  Since 2008
- Dusty Bowenkamp  Since 2013
- Sue & Gene Brenneman  Since 2018
- Seth Butler  Hike to Find A Cure For Chordoma  Since 2019
- Christopher & Stephen Capuzzi  Since 2017
- Nicholas Carr  Since 2018
- David Drewry  Since 2018
- Christina Ciocca Eller  The Henry G. Ciocca Champion Fund  Since 2018
- Stephanie Finley  Since 2018
- Aimee Howell  #TeamStephan  Since 2018
- Norma Jones  Since 2009
- Vanessa King  Christmas Surprise for Best Friend  Since 2018
- Maureen LaForge  Since 2018
- Samuel Leinoff  Since 2018
- Rachel Lichte  30-for-30 Birthday Challenge!  Since 2017
- John Mainey  Since 2018
- Steven Mandel  Since 2012
- Lamia Mandy  Since 2018
- Chris McCormley  Since 2018
- Facebook Milestones  Since 2015
- Ross and Ally Parks  Since 2017
- Michael Potempa  Since 2013
- Justin Remsen  Since 2018
- Colleen Riccomini  Since 2018
- Collecting donations in memory of her son
- Bart Salant  Since 2018
- Jaclyn Salant  Since 2018
- Matt Sauerhoff  Since 2016
- Dan Sauerhoff  Since 2018
- Maureen Schroer  Since 2013
- Robin Seitz  Since 2018
- Emily Sommer  Since 2018
- Kristin Stahl  The Marty Stahl Champion Fund  Since 2018
- Julie and Jeremy Trask  Since 2018
- Jaclyn Weissman & Zach Grauman  Since 2018

2018 Community Fundraising Events

- 10th Annual St. Paul’s Michael Galluccio Memorial Golf Outing  Mark Galluccio and Zach Feigman  Glen Cove, NY
- Blockbuster Bowling Benefit  Jeff Schilling  Kansas City, MO
- Brooklyn Half Marathon  Steven Mandel  London, UK
- Dawson’s Circle of Hope 5K  Susan Creager  Geneva, FL
- Dress Down Day  Lynette Nelson  Clifton, NJ
- Hike To Find A Cure For Chordoma  Seth Butler  Pownal, ME
- Infinity Fitness Day After Thanksgiving Workout  April Wallace  Scottsdale, AZ
- Make Mr. Whelan Look Silly  Marciszewski Family  Baltimore City, MD
- No Shave November  Nicholas Carr  Willimantown, NJ
- Olde Fashioned Colonial Christmas Home Tour  Gene and Sue Brenneman  Kinzers, PA
- Operation Support & Recover Ride  Rit Karena  Queensland, AU
- Pan-Mass Challenge  Todd Balf  Beverly, MA
- Pub Crawl for Chordoma  Colleen Riccomini  West Sayville, NY
- Riccomini Dodgeball Tournament  Colleen Riccomini  West Sayville, NY
- Skyline’s 10th Annual Charitable Gold Classic  The Skyline Charitable Foundation  Long Island City, NY
- Spirit Night Jess’s Battle Against Chordoma  Jessica McGeever  West Mifflin, PA
- Swing For a Cure in Honor of Hank Ciocca  Ciocca Family  New York, NY
- Swing Fore the Cure  Jeff Schilling and Maggie Bates  Kansas City, MO

18 community fundraising events
1,870+ donors around the world
37 online fundraising campaigns
Formed in 2018, the Accelerators Circle recognizes donors who make a gift of $25,000 or more over a 3-year period to speed the pace of progress.

We are deeply grateful to the following individuals, families, and organizations who joined the Accelerators Circle in 2018:

**Leader**

$500,000+
Anonymous (3)
The Beckman Family Foundation

**Benefactor**

$250,000 – $499,999
Mark Foundation for Cancer Research

**Patron**

$100,000 – $249,999
Anonymous
Richard and Susan Friedman
Esta Stecher

**Supporter**

$50,000 – $99,999
Anonymous
Joe and Christine McGovern
Grace and Andrew Schoellkopf

**Friend**

$25,000 – $49,999
Anonymous (2)
The Alpert Family Foundation
The Cedar Street Foundation
Celgene
Dawson’s Circle of Hope
The Drew Barker-Wright Charity
The Orokawa Foundation Inc.
Michael and Noreen Potempa
Megan and Joe Stewart
Helen Van Sickle Fund
Richard and Karen Westin

**$250K+**

Anonymous
The Beckman Family Foundation
Mark Foundation for Cancer Research

**$100K–249,999K**

Anonymous (3)
Richard and Susan Friedman
Esta Stecher

**$25K–99,999K**

Anonymous (4)
The Alpert Family Foundation
The Drew Barker-Wright Charity
The Cedar Street Foundation
Celgene
Dawson’s Circle of Hope
Joe and Christine McGovern
The Orokawa Foundation Inc.
Michael and Noreen Potempa
Grace and Andrew Schoellkopf
Megan and Joe Stewart
Helen Van Sickle Fund
Richard and Karen Westin

**$5K–9,999K**

Anonymous
Affiliated Foot Surgeons
Arthur and Karen Pappas
Norman R. and Margareta E. Augustine Bequest Fund
Robert and Frances Bridenbecker
Bright Funds Foundation
Burroughs Wellcome Fund
Richard and Ann Citarella
Richard and Janet Fell
G1 Therapeutics, Inc.
Lea Glazar
Global Genes - Allies in Rare Disease
Gary and Andrea Gold
Hughes Hubbard & Reed
Brooke and Carolyn Laney
Irene Lowe
Scott Miller
Stuart and Susan Porter
Drew Regitz
Renaissance Charitable Foundation, Inc.
Jeff and Erin Schilling
Mark and Laurie Slepicka
David and Peggy Tanner

**$1K–4,999K**

Anonymous (6)
AmazonSmile Foundation
American Century Investments
Ameriprise Financial
Yoram Amiga
Victoria Anderson
The Norman and Mary Anderton Charitable Fund
Shelba Barnes
Jaynee and Eric Beckman Family Fund
Benefit Community Impact Fund
Berg Family Fund
Stanley, Marion, Paul and Edward Bergman Family Foundation
Bespoke Partners, Inc.
David Biondi
Steve and Erin Bishop
Baltimore County Employees Federal Credit Union Board of Directors
Robert and Teresa Boccanfuso
Gene and Sue Brennan
John and Renee Butler
Douglas and Jen Call
Ann Marie Castenfelt
John Cochran
Kenny and Mona Cohen
Samuel Cohen
Collins Electric Co.
William and Sharon Connelly
Robert and Maureen Cooper
Frank Courtney

We’re grateful to the following donors who made our work possible in 2018:

**2018 Donors**

The Chordoma Foundation was a voice in the wilderness for our family after my husband Joe was diagnosed. We benefited so much from their information and encouragement – especially their help finding experienced doctors, which made all the difference in Joe’s outcome and recovery. Getting that help at such a frightening time gave us hope, and hope and gratefulness are powerful motivators. That’s why we joined the Accelerator’s Circle. Because we know that a strong Chordoma Foundation means a stronger and healthier chordoma community. And that’s an investment worth making.”

Megan Stewart
Wife of chordoma patient
Joe Stewart
$500–999
Anonymous (5)
Randy and Patricia Akers
American Express Foundation
Michael Arresco
Thomas and Nicole Armentrout
Kurtis Bachman
Paul and Karen Baer
Walter Bananto
Scott Barber and Jennifer Schwartz
Warren Barrett
Scott Bartholow
David and Laura Barton
Michele Barton
Karen Barwick
Jonathan and Margaret Bates
Mindy Berry
Sharon Berry
Dusty Bowenkamp
Alicia Brown
Nancy Buckman
Carol Bunt
Kelly Campbell
Peter Casanave and Naomi Nemtsov
Peter and Sharon Catto
Yen-Lin Chen
Michael Ciocca
Rita Ciocca
Cohen Feeley Altermore & Rambo, P.C.
Karen Cox
Daniel Dempsey and Barbara Seneza
Kate Egan
Marjory Eiler
Enterprise Bank & Trust
Lynn Etheredge Fund
Oliver Evans
Peter Fang
Russell and Virginia Flaum
Jeannine Fox
Gregory and Diane Fuchs
Cink Fundraising
Joan Funk
Andrew Gaasch
John Gally
William and Beverly Griffin
Arthur Hagar
Celia Hecht
Jeff and Diana Hewitt
Infinity Fitness AZ, LLC
Julia Jernigan
The Suzanne Nora Johnson & David G Johnson Foundation
Jeremy Johnson
Mark Konnick
Adalbert Koth
Jerald and Albertina Kuhn
Tzuchin Lee
Kara Leibel
Levy Holm Pellegrino & Drath LLP
Kenny Li
Richard and Susan Lichte
Andrew Little
MarksNelson LLC
Dolores Martinez
Jordan Marye
George Masnick and Reisa Kahn
Brea and Chris McCormley
Robert and Polly McCrea
Family Fund of the Minneapolis Foundation
Merck Foundation
Francis J. and Mary A. Meyer Charitable Fund
Emery Miller
Monsanto Matching Gift Program
Victoria Moran
Thomas Mass and Janie Deal
Artlynn Muckey
Christine Newfrock
Nancy Prendergast and Augusto Ribichard
Red Top Foundation
Alicia Reid
J. Robert and Nora Reinhardt
Scott Renner
Dietmar and Dorothy Riccomini
James Rittinger
Richard and Stacy Rosenthal
Adriane Rothstein and Mark Billy
Hans and Mary Lou Saeby
Sayville Union Free School District
The Shepard Broad Foundation, Inc.
Theodore and Katherine Shults
Scott Silverthorne
Gary Simon
Scott Smiley
Bruce and Maureen Smith
Matthew and Laura Soule
Mike Staveris
Strategic Enhancement Group Inc
Robert Switzer

We have made every attempt to ensure the accuracy of our donor list and we regret any errors or omissions. Please contact us at feedback@chordoma.org to correct any inaccuracies.

LEFT TO RIGHT
Foundation supporters Jeff Collins, Terri Mainey, Rose Mills, and John Mainey at our 2018 Board Retreat and appreciation dinner.
Financials

Audited statement of activities for the year ended December 31, 2018

<table>
<thead>
<tr>
<th>Revenue and support</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$ 2,314,783</td>
</tr>
<tr>
<td>In-kind contributions</td>
<td>166,405</td>
</tr>
<tr>
<td>Program service revenue</td>
<td>11,150</td>
</tr>
<tr>
<td>Interest</td>
<td>4,180</td>
</tr>
<tr>
<td><strong>Total revenue and support</strong></td>
<td><strong>$ 2,496,518</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expenses</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program services</td>
<td>$ 1,666,722</td>
</tr>
<tr>
<td>Management and general</td>
<td>306,030</td>
</tr>
<tr>
<td>Fundraising</td>
<td>439,268</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td><strong>$ 2,412,020</strong></td>
</tr>
</tbody>
</table>

Change in net assets  
Net assets, beginning of year  
Net assets, end of year  

A copy of our 2018 IRS Form 990 and audited financial statements are available at chordoma.org/financials

Looking ahead

Thanks to your investment and support, we’re on the cusp of some really big steps forward, particularly in the development of new therapies.

A growing pipeline of better chordoma treatments is on the way, and those facing the disease today now have a deep trove of trusted resources and support systems to aid in the journey.

But we won’t rest until everyone affected by chordoma is able to overcome the disease and maintain their quality of life. Here’s our plan of attack for 2019:

2019 Priorities

- **More support for patients and families**, including new educational content, new translations to reach more people worldwide, and more in-depth support from our Patient Navigation Service.
- **Greater progress in clinical trials**, including increasing patient participation, completing enrollment milestones for ongoing CF-supported trials, and launching at least one new trial.
- **Expanded investment in brachyury drug discovery**, including follow-on funding for current collaborators whose research has proven successful, and new grants for pre-vetted, high-impact proposals.
- **New investments in cutting-edge science** aimed at attacking chordoma through epigenetics and immunotherapies.

We look forward to working with you to make this progress possible!
Our staff

Josh Sommer
Executive Director

Daniel Baroff
Development Manager

Patty Cogswell
Manager of Research

Larry Gottschalk
Operations Coordinator

Chase Hinnant
Patient Services Coordinator

Joan Levy, PhD
Director of Research

Shannon Lozinsky, MSW
Director of Patient Services

Breanna McCormley
Director of Development

Jennifer Roeder
Marketing and Communications Manager

Tammy Silverthorne
Director of Operations

Gillian Parrish
Communications Consultant

Our team

Members of our Board of Directors, staff, and special guests at our 2018 Board Retreat.

Our team

LEFT

Our team

Board of Directors

Andrew Schoellkopf
Chair

Joel Beckman
Vice Chair

Ingemar Lanevi
Treasurer

David Drewry, PhD

Steven Mandel

Shreyas Patel, MD

David Sandak

Christy Shaffer, PhD

Kerry Shad, JD*

Josh Sommer

Paula Song, PhD

Board committees

FINANCE

Ingemar Lanevi
Chair

Mark Ricca

Andrew Schoellkopf

RESEARCH

Kurt Bachman, PhD

Jeffrey Collins, PhD

David Drewry, PhD

Shreyas Patel, MD

William Phelps, PhD

David Sandak

Chandra Sen, MD

John Therien, JD

PATIENT SERVICES

Paula Song, PhD
Chair

Karen Cox, PhD, RN

Vickie Leff, LCSW**

Michael O’Brien, MSW, LICSW

DEVELOPMENT

Joel Beckman
Chair

Anne Noel Dawson

Steven Mandel

Andrew Schoellkopf

Joe Villinski

NOMINATING

Joel Beckman
Chair

Edward Les, MD

Andrew Schoellkopf

Christy Shaffer, PhD

EXECUTIVE

Andrew Schoellkopf
Chair

Joel Beckman

Ingemar Lanevi

David Sandak

Kerry Shad, JD*

Scientific Advisory Board

David Drewry, PhD

Adrienne Flanagan, MD, PhD

Fran Hurni, MD, PhD

Michael Kelley, MD

Paul Meltzer, MD, PhD

Deric Park, MD

Medical Advisory Board

Shreyas Patel, MD
Chair

Greg Cota, MD, PhD

Tom DeLaney, MD

Paul Gardner, MD

Hans Gelderblom, MD, PhD

Ziya Gokaslan, MD

Minal Gounder, MD

Christopher Heery, MD

Fran Hurni, MD, PhD

Chandra Sen, MD

Silvia Stacchiotti, MD

Katie Thornton, MD

Josh Yamada, MD

Community Advisory Board

Chris Jones
Chair

Edward Les, MD
Medical Liaison

Sue Brenneman

Susan Garbett

Steven Golick

Caroline Kooy

Maureen LaForge

Heather Lee, PhD

Steven Mandel

Joe McGovern

Jeff Schilling

Tim Zellers

*Through November 2018

**Through June 2018

*Through November 2018

**Through June 2018

Our staff outside the Broad Institute in Cambridge, MA. Not pictured: Larry Gottschalk and Jennifer Roeder.
I have been so impressed with what the Chordoma Foundation and the chordoma community have accomplished together. It gives me great hope that the years ahead will be even more promising.”